prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - antígenos de superficie del virus de la gripe (hemaglutinina y neuraminidasa) de la cepa a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacunas - inmunización activa contra el subtipo h5n1 del virus influenza a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
lamicosil uni 10 mg/g solucion cutanea
glaxosmithkline consumer healthcare, s.a. - terbinafina hidrocloruro - soluciÓn cutÁnea - 10 mg/g - terbinafina hidrocloruro 10 mg - terbinafina
lamicosil 10 mg/g crema
glaxosmithkline consumer healthcare, s.a. - terbinafina hidrocloruro - crema - 10 mg/g - terbinafina hidrocloruro 10 mg - terbinafina
venoruton 20 mg/g gel
glaxosmithkline consumer healthcare, s.a. - troxerutina - gel - 20 mg/g - troxerutina 20 mg - troxerutina
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptina, metformin hidrocloruro - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).
cosentyx (secukinumab) 150 mg/ml solucion inyectable en jeringa prellenada
novartis de venezuela s.a. - secukinumab -
cosentyx (secukinumab) 150mg polvo liofilizado para solucion inyectabl
novartis de venezuela, s.a. - secukinumab -
signifor lar 20 mg polvo para suspension inyectable
novartis de venezuela, s.a. - pasireotida - polvo para suspension inyectable - 20 mg
signifor lar 40 mg polvo para suspension inyectable
novartis de venezuela, s.a. - pasireotida - polvo para suspension inyectable - 40 mg
signifor lar 60 mg polvo para suspension inyectable
novartis de venezuela, s.a. - pasireotida - polvo para suspension inyectable - 60 mg